Home › Breast Cancer › Tennessee › Chattanooga
Breast Cancer clinical trials in Chattanooga, TN
3 studies for Breast Cancer are looking for participants at sites in and around Chattanooga (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RecruitingPhase 3
- Research Site, Chattanooga
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RecruitingPhase 1/2
- Tennessee Oncology - Chattanooga Oncology & Hematology Associates, Chattanooga
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RecruitingPhase 2
- Sarah Cannon Research Institute, Chattanooga
About Breast Cancer
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. These extra cells can form a mass called a tumor.
More about Breast Cancer on MedlinePlus
Breast Cancer trials in other cities
- New York City, NY136 studies
- Houston, TX126 studies
- Boston, MA112 studies
- Nashville, TN81 studies
- Los Angeles, CA73 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Queens, NY64 studies
- Durham, NC64 studies
- Chicago, IL59 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Other studies in Chattanooga
- Non-Small Cell Lung Cancer11 studies
- Metastatic Cancer6 studies
- Myasthenia Gravis6 studies
- Ovarian Cancer5 studies
- Diabetes4 studies
- Steatotic Liver Disease4 studies
- Melanoma4 studies
- Ischemic Stroke4 studies
- Colorectal Cancer4 studies
- Chronic Kidney Disease4 studies
- Lung Cancer4 studies
- Kidney Failure3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.